

## Accepted Manuscript

Title: Dynamin-related protein Drp1 and mitochondria are important for *Shigella flexneri* infection

Author: Mabel Lum Renato Morona

PII: S1438-4221(14)00027-7  
DOI: <http://dx.doi.org/doi:10.1016/j.ijmm.2014.03.006>  
Reference: IJMM 50808

To appear in:

Received date: 5-2-2014  
Revised date: 17-3-2014  
Accepted date: 24-3-2014

Please cite this article as: Lum, M., Morona, R., Dynamin-related protein Drp1 and mitochondria are important for *Shigella flexneri* infection, *International Journal of Medical Microbiology* (2014), <http://dx.doi.org/10.1016/j.ijmm.2014.03.006>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Title: Dynamin-related protein Drp1 and mitochondria are important for *Shigella flexneri***  
2 **infection**

3

4 **Authors:** Mabel Lum, Renato Morona\*

5

6 **Address:** School of Molecular and Biomedical Science, University of Adelaide, Adelaide, South  
7 Australia, Australia

8

9 **Contact details:**

10 \* E-mail: [renato.morona@adelaide.edu.au](mailto:renato.morona@adelaide.edu.au)

11 Tel: 61 8 8313 4151

12 Fax: 61 8 8313 7532

13

14

14

15 **Abstract**

16 *Shigella* infection in epithelial cells induces cell death which is accompanied by mitochondrial  
17 dysfunction. In this study the role of the mitochondrial fission protein, Drp1 during *Shigella*  
18 infection in HeLa cells was examined. Significant lactate dehydrogenase (LDH) release was  
19 detected in the culture supernatant when HeLa cells were infected with *Shigella* at a high  
20 multiplicity of infection. Drp1 inhibition with Mdivi-1 and siRNA knockdown significantly  
21 reduced LDH release. HeLa cell death was also accompanied by mitochondrial fragmentation.  
22 Tubular mitochondrial networks were partially restored when Drp1 was depleted with either  
23 siRNA or inhibited with Mdivi-1. Surprisingly either Mdivi-1 treatment or Drp1 siRNA-  
24 depletion of HeLa cells also reduced *Shigella* plaque formation. The effect of Mdivi-1 on  
25 *Shigella* infection was assessed using the murine Sereny model, however it had no impact on  
26 ocular inflammation. Overall our results suggest that Drp1 and the mitochondria play important  
27 roles during *Shigella* infection.

28

29 **Keywords:**30 *Shigella flexneri*

31 Cell death

32 Cell spreading

33 Drp1

34 Mitochondria

35 Mdivi-1

36

36

37 **Introduction**

38 *Shigella flexneri* is the causative agent of bacillary dysentery (shigellosis) and is a significant  
39 human pathogen due to its high morbidity among children < 5 years in developing countries  
40 (Bardhan et al., 2010). The key pathogenic features of *Shigella* include cell death induction in  
41 myeloid immune cells and circumventing cell death in colonic epithelial cells, the site of *Shigella*  
42 infection. *Shigella* also interact with host proteins to initiate de novo actin synthesis to facilitate  
43 its intra- and intercellular spread to disseminate within the colon.

44

45 Post ingestion of contaminated food and water, *Shigella* initially invades the host intestinal  
46 epithelium via microfold cells and induce pyroptosis of the resident macrophages in the follicle  
47 associated epithelium by activating ICE protease-activating factor-dependent (IPAF/NLRC4)  
48 and apoptosis-associated speck-like protein containing caspase recruitment domain (ASC)  
49 inflammasome (Senerovic et al., 2012; Suzuki et al., 2007). Subsequent caspase-1 activation  
50 releases interleukin-1 $\beta$  (IL-1 $\beta$ ) and interleukin-18 (IL-18), resulting in strong inflammatory  
51 responses and magnified innate responses, respectively (Sansone et al., 2000). Another form of  
52 necrotic cell death induced in macrophage is pyronecrosis, which is independent of caspase-1  
53 activation and releases another proinflammatory factor, HMGB1 (high-mobility group box 1  
54 protein) (Willingham et al., 2007).

55

56 Following macrophage pyroptosis, *Shigella* are released into the basolateral compartment and  
57 invade enterocytes via the type three secretion system (TTSS), followed by lysis of the endocytic  
58 vacuole and replication in the cytoplasm (Cossart and Sansone et al., 2004; Sansone et al., 1986).  
59 The polarly localised *Shigella* IcsA protein interacts with the host N-WASP (Neural Wiskott-  
60 Aldrich syndrome protein) and Arp2/3 complex to initiate F-actin nucleation and polymerisation,  
61 leading to actin based motility which allows the bacterium to spread within the cytoplasm and  
62 also laterally via protrusion formation into the adjacent cells (Bernardini et al., 1989; Lett et al.,  
63 1989; Makino et al., 1986). After escaping from the double membrane vacuole, subsequent  
64 cycles of infection are initiated (Schuch et al., 1999). Proteins localised at the enterocyte tight  
65 junctions and adherens junctions facilitate *Shigella* protrusion formation and may associate  
66 directly with the *Shigella* actin tail (Bishai et al., 2012; Kadurugamuwa et al., 1991; Sansone et

67 al., 1994). *Shigella* invasion and dissemination is also dependent on ATP release by connexion  
68 26 and formins, Dia1 and Dia2, which can initiate de novo actin polymerisation and crosslink  
69 actin filaments (Heindl et al., 2009; Tran Van Nhieu et al., 2003). Components of the clathrin  
70 mediated endocytosis pathway also facilitate *Shigella* entry into the adjacent cell (Fukumatsu et  
71 al., 2012; Lum et al., 2013).

72

73 Eliminating infected enterocytes prevents *Shigella* from propagating and disseminating into  
74 uninfected cells (Ashida et al., 2011). However *Shigella* is able to delay cell death by  
75 manipulating host signalling pathways. Depending on the experimental conditions such as host  
76 cell type, time of infection and multiplicity of infection (moi), apoptotic and necrotic cell death  
77 have been observed during *Shigella* infection. Apoptosis is a non-inflammatory cell death which  
78 is activated by mitochondria and death receptor mediated pathways characterised by caspase  
79 activation, DNA fragmentation, cell shrinkage, membrane blebbing and mitochondrial  
80 permeability (Lamkanfi and Dixit, 2010), whereas necrosis is characterised by nuclear swelling,  
81 membrane rupture and spillage of cellular contents into the environment resulting in  
82 inflammatory conditions. Absence of caspase activation, reactive oxygen species (ROS)  
83 production, lysosomal destabilization, calpain release and ATP depletion are also observed  
84 (Golstein and Kroemer, 2007; Vandenabeele et al., 2010).

85

86 *Shigella* infection in HeLa cells induces an early genotoxic stress (Bergounioux et al., 2012).  
87 The tumour suppressor protein p53, an inducer of apoptosis is normally stabilised during  
88 genotoxic response. However p53 is rapidly degraded by calpain, through degradation of the  
89 calpain protease inhibitor, calpastatin, by the *Shigella* VirA TTSS effector (Bergounioux et al.,  
90 2012). Calpain activation inadvertently activates the necrosis pathway which restricts *Shigella*  
91 intracellular growth (Bergounioux et al., 2012). In the colonic HCT116 cells, the slow  
92 degradation of p53 shifts the executing pathway from necrosis to apoptosis (Bergounioux et al.,  
93 2012). In HaCat (immortalized keratinocytes) cells, the *Shigella* TTSS effector, OspC3 targets  
94 the p19 subunit of Caspase-4 to delay necrotic cell death (Kobayashi et al., 2013). In vivo the  
95  $\Delta ospC3$  mutant exacerbates colonic inflammation in guinea pigs (Kobayashi et al., 2013). In  
96 HeLa cells and mouse embryonic fibroblasts (MEFs), pro-survival Nod1/NF- $\kappa$ B/Bcl-2 signalling  
97 is activated to counteract the necrotic pathway mediated by Bnip3, a regulator of mitochondrial

98 permeability transition during *Shigella* infection (Carneiro et al., 2009). In staurosporine (STS)-  
99 induced apoptosis in HeLa cells, the *Shigella* Spa15 (TTSS) effector prevented caspase-3  
100 activation (Faherty and Maurelli, 2009). *Shigella* infection in HeLa cells and in an ex vivo  
101 colonic epithelial cell model reportedly triggered apoptosis via caspase-9 and caspase-3  
102 activation (Lembo-Fazio et al., 2011). Furthermore Gadd45a (stress sensor growth arrest and  
103 DNA damage 45a), a stress-inducible gene, was also upregulated in vitro and ex vivo (Lembo-  
104 Fazio et al., 2011).

105

106 Mitochondrial fission is an important downstream event for intrinsic apoptotic and programmed  
107 necrosis signalling pathways (Otera et al., 2013). Mitochondrial constriction is initially mediated  
108 by the endoplasmic reticulum and actin (Friedman et al., 2011; Korobova et al., 2013). Dimeric  
109 or tetrameric cytosolic dynamin-related protein 1 (Drp1, also known as dynamin-1-like protein)  
110 is then recruited to fission sites on the mitochondria to its receptor, Mff (Otera et al., 2010). In  
111 the presence of GTP, Drp1 self-assembly stimulates GTP hydrolysis and formation of higher  
112 order structures as foci at the mitochondrial fission sites (Smirnova et al., 2001). Oligomerised  
113 Drp1 wraps around the mitochondria and following GTP hydrolysis, the mitochondrial  
114 membrane is severed (Smirnova et al., 2001). Drp1 assembly on the mitochondria is inhibited by  
115 the small molecule inhibitor, mitochondrial division inhibitor-1 (Mdivi-1) through interactions  
116 with an allosteric site which does not affect its GTPase activity (Cassidy-Stone et al., 2008).  
117 Mdivi-1 has therapeutic effects in various animal models of non-infectious diseases (Ferrari et  
118 al., 2011; Ong et al., 2010; Tang et al., 2013).

119

120 Previously we reported that dynasore, an inhibitor of dynamin II and Drp1 GTPase activity  
121 affected *Shigella* cell spreading and *Shigella*-induced cytotoxicity in HeLa cells. Furthermore  
122 dynasore also protected mice from weight loss in an ocular infection model even though  
123 inflammation was not reduced (Lum et al., 2013). We decided to investigate if Drp1 contributed  
124 to the observations we made earlier. In this study HeLa cells were infected with *Shigella* at a moi  
125 (multiplicity of infection) of 500 and 1000. During *Shigella* infection, lactate dehydrogenase  
126 (LDH) was released into the culture supernatant. HeLa cells treated with a pan-caspase inhibitor  
127 did not reduce LDH release and caspase-3 was not activated, suggesting *Shigella* induces non-  
128 apoptotic cell death under these conditions. Drp1 inhibition with Mdivi-1 and Drp1 depletion

129 with siRNA reduced LDH release. Mitochondrial fragmentation was also observed in *Shigella*-  
130 infected cells and was partially restored when HeLa cells were either treated with Mdivi-1 or  
131 when Drp1 was depleted with siRNA. Unexpectedly *Shigella* plaque formation was reduced in  
132 Mdivi-1-treated HeLa cells. This was also observed in HeLa cells knockdown with Drp1 siRNA,  
133 suggesting maintaining mitochondria structure is important for efficient cell spreading. A murine  
134 Sereny test was used to determine if Mdivi-1 could reduce keratoconjunctivitis or protect mice  
135 from weight loss due to *Shigella* infection. Mdivi-1 treatment did not reduce ocular inflammation  
136 but did protect mice from weight loss in the first 24 h only. These results suggest Drp1 and the  
137 mitochondria are critical for *Shigella* infection.

138

## 139 **Materials and methods**

### 140 **Bacterial strains and growth media**

141 The strains used in this study are listed in Table 1. *S. flexneri* strains were grown from a Congo  
142 Red positive colony as described previously (Morona et al., 2003) and were routinely cultured in  
143 Luria Bertani (LB) broth and on LB agar. Virulence plasmid-cured (VP<sup>-</sup>) derivative of WT *S.*  
144 *flexneri* strain was isolated on Congo Red agar as white colonies and re-streaked until pure  
145 (Morona and Van Den Bosch, 2003). Bacteria were grown in media for 16 h with aeration,  
146 subcultured 1/20 and then grown with aeration to mid-exponential growth phase for 1.5 h at  
147 37°C. Where appropriate, media were supplemented with tetracycline (4 or 10 µg/mL).

148

### 149 **Chemicals and antibodies**

150 IM-54 (5 mM stock - ALX-430137; Enzo Life Sciences), Mdivi-1 (50 mM stock - M0199;  
151 Sigma-Aldrich, BML-CM127; Enzo Life Sciences), Necrostatin-1 (100 mM stock - N9037;  
152 Sigma-Aldrich), Necrostatin-7 (20 mM stock - ALX-430-170; Enzo Life Sciences),  
153 Necrosulfonamide (20 mM stock - N388600; Toronto Research Chemicals), NecroX-2 (5 mM  
154 stock - ALX-430-166; Enzo Life Sciences), NecroX-5 (5 mM stock - ALX-430-167; Enzo Life  
155 Sciences), Staurosporine (10 mM stock - 00025, Biotium), Z-FA-FMK (20 mM stock - 550411;  
156 BD Biosciences) and Z-VAD-fmk (20 mM stock - Merck Calbiochem; 627610) were prepared in  
157 dimethyl sulfoxide (DMSO) (D2650; Sigma-Aldrich) for in vitro studies. For in vivo studies,  
158 Mdivi-1 was dissolved in a formulation containing 1-methyl-2-pyrrolidone (NMP/Pharmasolve;  
159 Ashland ISP) and polyethylene glycol 300 (PEG300; Sigma-Aldrich) (1 part NMP to 9 parts

160 PEG300). Mdivi-1 was prepared as a 22 mg/mL stock and diluted 1/4 (5.5 mg/mL) with  
161 NMP/PEG before injection into mice. Mouse anti-DLP1 antibody (611112; BD Biosciences) and  
162 rabbit anti-GAPDH antibody (600-401-A33; Rockland Immunochemicals, Inc.) were used at  
163 1:100 and 1:3000 for Western immunoblotting, respectively. For immunofluorescence (IF)  
164 microscopy, rabbit anti-active (cleaved) caspase-3 antibody (AB3623; Merck Milipore), anti-  
165 DLP1 antibody, Alexa 594-conjugated donkey anti-mouse secondary antibody and Alexa Fluor  
166 594-conjugated donkey anti-rabbit antibody (Molecular Probes) were used at 1:100.

167

### 168 **Reverse transfection and HeLa cell lysate preparation**

169 DNMI1L siRNA (L012092-00-0005) and siRNA controls (Non-targeting Pool; D-001810-10-05,  
170 siGLO Green Transfection Indicator; D-001630-01-05) were purchased from Thermo Scientific.  
171 siRNAs were transfected with DharmaFECT 3 Transfection Reagent (T-2003-03) and  
172 DharmaFECT Cell Culture Reagent (DCCR; B-004500-100), also purchased from Thermo  
173 Scientific. Reverse transfection of HeLa cells (Human, cervical, epithelial cells ATCC #CCL-70)  
174 were carried out based on a method by Thermo Scientific. siRNA were prepared as a 5  $\mu$ M stock  
175 and the final concentration used was 50 nM. HeLa cells were transfected and cell lysates were  
176 prepared as described previously (Lum et al., 2013).

177

### 178 **SDS-PAGE and Western immunoblotting**

179 SDS-PAGE (12% acrylamide gel) and Western immunoblotting were carried out as described  
180 previously (Lum et al., 2013). Molecular weight markers used were BenchMark™ Pre-Stained  
181 Protein Ladder (Invitrogen).

182

### 183 **Plaque assay**

184 Plaque assays were performed with HeLa cells as described previously by Oaks *et al.* (Oaks et  
185 al., 1985) with modifications. HeLa cells were transfected in 12-well trays prior to plaque assay  
186 as described previously (Lum et al., 2013). On day 4, the plaque assay was carried out when the  
187 cells reached confluency. HeLa cells were washed twice with Dulbecco's modified Eagle  
188 medium (DMEM) prior to inoculation.  $5 \times 10^4$  mid-exponential phase bacteria were added to  
189 each well. Trays were incubated at 37°C, 5% CO<sub>2</sub> and were rocked gently every 15 min to  
190 spread the inoculum evenly across the well. At 90 min post infection, the inoculum was



191 aspirated. 0.5 mL of the first overlay (DMEM, 5% FCS, 20 µg/mL gentamicin, 0.5% (w/v)  
192 agarose [Seakem ME]) was added to each well. The second overlay (DMEM, 5% FCS, 20  
193 µg/mL gentamicin, 0.5% (w/v) agarose, 0.1% (w/v) Neutral Red solution [Gibco BRL]) was  
194 added 24 h post infection and plaques were imaged 6 h later. All observable plaques were  
195 counted and the diameter was measured for each condition in each experiment. At least 50  
196 plaques were measured for each condition.

197

### 198 **Infectious focus assay**

199  $1.2 \times 10^6$  HeLa cells were seeded in six-well trays in minimal essential medium (MEM), 10%  
200 FCS, 1% penicillin/streptomycin. Cells were grown to confluence overnight and were washed  
201 twice with DMEM prior to inoculation.  $5 \times 10^4$  mid-exponential phase bacteria expressing  
202 mCherry were added to each well. Trays were incubated at 37°C, 5% CO<sub>2</sub> and were rocked every  
203 15 min to spread the inoculum evenly across the well. At 90 min post infection, the inoculum  
204 was aspirated. 1.5 mL of DMEM (phenol red-free) (31053-028; Life Technologies), 1 mM  
205 sodium pyruvate, 5% FCS, 20 µg/mL gentamicin, 2 mM IPTG was added to each well. Mdivi-1  
206 or DMSO were added and were swirled to ensure even distribution. 24 h later the infectious foci  
207 were imaged with an Olympus IX-70 microscope using a 10× objective. The filter set used was  
208 DA/FI/TX-3X-A-OMF (Semrock). Fluorescence and phase contrast images were captured and  
209 false colour merged with the Metamorph software program (Version 7.7.3.0, Molecular  
210 Devices). The area of the infectious focus, i.e. area where mCherry was expressed, was outlined  
211 and measured with Metamorph. All observable infectious foci were counted and the area was  
212 measured for each condition in each experiment. At least 5 infectious foci were measured for  
213 each condition.

214

### 215 **Invasion assay and IF microscopy**

216 HeLa cells ( $8 \times 10^4$ ) were seeded onto sterile glass cover slips in 24-well trays in MEM, 10%  
217 FCS, 1% penicillin/streptomycin. For transfected cells, HeLa cells were transfected as described  
218 previously (Lum et al., 2013). Cells were grown to semi-confluence overnight, washed twice  
219 with Dulbecco's PBS (D-PBS) and once with MEM, 10% FCS.  $4 \times 10^7$  mid-exponential phase  
220 bacteria were added to each well and subsequently centrifuged (2,000 rpm, 7 min, Heraeus  
221 Labofuge 400 R) onto HeLa cells. After 1 h incubation at 37°C, 5% CO<sub>2</sub>, the infected cells were

222 washed thrice with D-PBS and incubated with 0.5 mL MEM containing 40  $\mu\text{g}/\text{mL}$  of gentamicin  
223 for a further 1.5 h (or 3.5 h for labelling with anti-activated caspase-3). Infected cells were  
224 washed thrice in D-PBS, fixed in 3.7% (v/v) formalin for 15 min, incubated with 50 mM  $\text{NH}_4\text{Cl}$   
225 in D-PBS for 10 min, followed by permeabilisation with 0.1% Triton X-100 (v/v) for 5 min.  
226 After blocking in 10% FCS in PBS, the infected cells were incubated at 37°C for 30 min with the  
227 desired primary antibody. After washing in PBS, coverslips were incubated with either Alexa  
228 Fluor 594-conjugated donkey anti-mouse or Alexa 594-conjugated donkey anti-rabbit secondary  
229 antibody (Molecular Probes) (1:100). F-actin was visualised by staining with Alexa Fluor 488-  
230 conjugated phalloidin (2 U/mL) and 4',6'-diamidino-2-phenylindole (DAPI) (10  $\mu\text{g}/\text{mL}$ ) was  
231 used to counterstain bacteria and HeLa cell nuclei. Coverslips were mounted on glass slides with  
232 Mowiol 4-88 (Calbiochem) containing 1  $\mu\text{g}/\text{mL}$  *p*-phenylenediamine (Sigma) and was imaged  
233 using a 100 $\times$  oil immersion objective (Olympus IX-70). The filter set used was DA/FI/TX-3X-  
234 A-OMF (Semrock). Fluorescence and phase contrast images were false colour merged using the  
235 Metamorph software program.

236

#### 237 **MitoTracker® Red CMXRos labelling**

238 HeLa cells were seeded and infected as described in "*Invasion assay and IF microscopy*". The  
239 infected cells were washed thrice with D-PBS and incubated with 0.5 mL MEM containing 40  
240  $\mu\text{g}/\text{mL}$  of gentamicin for 2 h 55 min. The media was removed and replaced with pre-warmed 400  
241 nM MitoTracker® Red CMXRos (Invitrogen) in MEM, 40  $\mu\text{g}/\text{mL}$  gentamicin for 35 min. HeLa  
242 cells were washed thrice with pre-warmed D-PBS, fixed in pre-warmed 3.7% (v/v) formalin for  
243 15 min, followed by three washes with pre-warmed PBS. Bacteria and HeLa cell nuclei were  
244 stained with 10  $\mu\text{g}/\text{mL}$  DAPI in MQ water for 1.5 min at RT, followed by two washes with pre-  
245 warmed PBS and one wash with pre-warmed mQ water. Cover slips were mounted and imaged  
246 using a 100 $\times$  oil immersion objective as described in "*Invasion assay and IF microscopy*".

247

#### 248 **Protrusion formation**

249 HeLa cells were seeded, infected and fixed as per "*Invasion assay and IF microscopy*". HeLa  
250 cells were washed twice with 1 $\times$  Annexin V binding buffer (99902; Biotium) prepared in milliQ  
251 (18.2 M $\Omega$ ·cm) water, mounted on glass slides with the same buffer and were imaged using a 40 $\times$   
252 oil immersion objective (Olympus IX-70). Protrusion formation was defined as any extensions of

253 bacterial projection(s) (minimum of a full bacterial length) beyond the periphery of the HeLa  
254 cell. For each condition in each experiment, a minimum of 100 cells were imaged.

255

#### 256 **Assay for growth of intracellular bacteria**

257 HeLa cells ( $8 \times 10^4$ ) were seeded in 24-well trays in MEM, 10% FCS, 1%  
258 penicillin/streptomycin. Cells were grown to semi-confluence overnight, washed twice with D-  
259 PBS and once with MEM, 10% FCS.  $4 \times 10^7$  mid-exponential phase bacteria were added to each  
260 well (moi 500) and were centrifuged (2,000 rpm, 7 min, Heraeus Labofuge 400 R) onto HeLa  
261 cells. After 1 h incubation at 37°C, 5% CO<sub>2</sub>, the infected cells were washed thrice with D-PBS  
262 and incubated with 0.5 mL MEM containing 40 µg/mL of gentamicin. At the indicated intervals,  
263 monolayers (in duplicate) were washed four times in D-PBS and were lysed with 0.1% (v/v)  
264 Triton X-100 in PBS for 5 min and bacteria were enumerated on tryptic soy agar (TSA; Gibco)  
265 plates.

266

#### 267 **LDH cytotoxicity assay**

268 HeLa cells ( $3 \times 10^4$ ) were seeded in 96-well trays in MEM, 10% FCS, 1%  
269 penicillin/streptomycin. Cells were grown to confluence overnight and were washed twice with  
270 PBS. 50 µL phenol-red free DMEM, 1 mM sodium pyruvate and  $3 \times 10^7$  mid-exponential phase  
271 bacteria (moi 1000) in 50 µL PBS or PBS were added into each well, where appropriate. The  
272 bacteria were centrifuged (2,000 rpm, 7 min, Heraeus Labofuge 400 R) onto HeLa cells. After 1  
273 h incubation at 37°C, 5% CO<sub>2</sub>, the infected cells were washed thrice with PBS and incubated  
274 with 0.1 mL phenol-red free MEM, 40 µg/mL of gentamicin for 4 h. LDH activity was measured  
275 with the Cytotoxicity Detection Kit<sup>Plus</sup> as per manufacturer's instructions (Roche). The  
276 percentage of LDH released was calculated with the following formula: ((experimental LDH  
277 release – spontaneous LDH release) / (maximal LDH – spontaneous LDH release)) × 100.

278

#### 279 **Ethics statement**

280 The use of animals in this study has been approved by the University of Adelaide Animal Ethics  
281 Committee (Project number: S-2012-90). All animals used were handled in compliance with the  
282 Australian code of practice for the care and use of animals for scientific purposes, 7th edition  
283 (2004).

284

**285 Mouse Sereny test**

286 The mouse Sereny test (Murayama et al., 1986) was carried out as described previously (Lum et  
287 al., 2013). Male Balb/c mice (20-22g) were inoculated with  $2.5 \times 10^7$  CFUs bacteria in 5  $\mu$ L of  
288 bacterial suspension (in PBS) into the right eye; the left eye served as a diluent control. To  
289 ascertain the impact of Mdivi-1 on ocular infection, mice were injected intraperitoneally (IP)  
290 with drug at a dose rate of 30 mg/kg, at t = -1, +6, +23 and +30 hours with respect to infection at  
291 0 hours. Keratoconjunctivitis was evaluated at specific time points after inoculation and scored  
292 on a scale ranging from 0 (no infection), 1 (mild keratoconjunctivitis where the eye lid is slightly  
293 swollen), 2 (severe keratoconjunctivitis where the eye is half closed) and 3 (fully developed  
294 keratoconjunctivitis where the eye is completely closed). Due to an ethics concern with the in  
295 vivo use of DMSO, Mdivi-1 was prepared in NMP/PEG, which is made up of 1 part 1-methyl-2-  
296 pyrrolidione (NMP) and 9 parts polyethylene glycol 300 (PEG300). A preliminary mouse study  
297 showed that this dosing regime resulted in 10% weight loss over a period of 72 h (Fig. S1).

298

**299 Statistical analysis**

300 Statistical analysis was carried out using GraphPad Prism 6. Results are expressed as means  $\pm$   
301 SEM of data obtained in independent experiments. Statistical differences between two groups  
302 were determined with a two-tailed unpaired *t*-test. Statistical differences between three or more  
303 groups were determined with a one-way ANOVA followed by Tukey's multi comparison post  
304 hoc test. Statistical significance was set at  $p < 0.05$ .

305

**306 Results****307 *S. flexneri* induces Drp1-mediated cell death in HeLa cells**

308 In a preliminary experiment, we investigated the effects of *S. flexneri* moi on LDH release. HeLa  
309 monolayers were infected with WT or virulence plasmid-cured (VP<sup>-</sup>) *S. flexneri* at moi ranging  
310 from 1 - 1000 (Fig. S2). HeLa cells infected with WT *Shigella* at moi of  $\geq 100$  had significantly  
311 higher LDH release compared to the VP<sup>-</sup> strain. Moi of 500 and 1000 was used in this study to  
312 reflect the experimental conditions used previously (Lum et al., 2013). No difference in LDH  
313 release was observed between moi 500 and 1000 (Fig. S2).

314

315 Recently we reported that dynasore, a non-competitive, reversible inhibitor of dynamin II and  
316 Drp1 GTPase activity significantly reduced *S. flexneri*-induced cytotoxicity in HeLa cells (Lum  
317 et al., 2013). The efficacy of dynasore was also tested in a murine ocular infection model. Mice  
318 treated with dynasore lost significantly less weight compared to mice treated with the NMP/PEG  
319 vehicle, however no improvement in ocular inflammation was observed. These results prompted  
320 us to examine the role of Drp1, if any, during *S. flexneri* pathogenesis. We initially investigated  
321 if *S. flexneri*-induced HeLa cytotoxicity was mediated by the mitochondrial fission protein,  
322 Drp1. The effects of Mdivi-1, a Drp1 inhibitor, and Drp1 siRNA on LDH release were  
323 determined. HeLa monolayers infected with *S. flexneri* (moi 1000) were treated with increasing  
324 concentrations of Mdivi-1 or with the DMSO control alone. *Shigella*-infected DMSO-treated  
325 HeLa cells released high levels of LDH ( $43.68 \pm 0.85\%$ ). In HeLa cells treated with 50  $\mu\text{M}$   
326 Mdivi-1, LDH release was significantly reduced ( $32.70 \pm 0.47\%$ ) and further reduction was  
327 observed with 100  $\mu\text{M}$  Mdivi-1 treatment ( $24.06 \pm 2.70$ ) (Fig. 1A). To investigate the effect of  
328 Drp1 depletion on *S. flexneri*-induced cytotoxicity, HeLa cells were transfected with Drp1  
329 siRNA and LDH release by infected cells was measured. Western immunoblots of HeLa cell  
330 lysates two days post siRNA treatment showed no detectable Drp1 levels (Fig. 1B). LDH release  
331 induced by *S. flexneri* was significantly reduced in HeLa cells treated with Drp1 siRNA ( $*p <$   
332  $0.05$ ) (Fig. 1C).

333

### 334 ***S. flexneri* induces non-apoptotic cell death in HeLa cells**

335 Since Drp1 have been implicated in both apoptosis and necrosis, we determined if components  
336 of the apoptotic or necrotic cell death pathways were involved. Uninfected HeLa monolayers  
337 were treated with the DMSO control or positive control agents; staurosporine (STS) to induce  
338 apoptosis or 0.01% Triton X-100 to induce necrosis (Kwon et al., 2011) (Fig. 2A). LDH release  
339 was observed in HeLa cells treated with 0.01% Triton X-100 but not STS. The effects of Z-  
340 VAD-fmk, a pan-caspase inhibitor and its inactive analogue, Z-FA-fmk, on LDH release during  
341 *S. flexneri* infection were determined. HeLa monolayers infected with *S. flexneri* were treated  
342 with increasing concentrations of Z-VAD-fmk or Z-FA-fmk or the DMSO control. No reduction  
343 in LDH release was observed (Fig. 2B and 2C). Caspase-3 cleavage is indicative of apoptosis  
344 activation (Reed, 2000). We investigated activated caspase-3 localisation in untreated, DMSO-  
345 treated, STS-treated and *S. flexneri*-infected (moi 500) HeLa cells (Fig. S3A - 3D). Activated

346 caspase-3 was only observed in HeLa cells treated with STS (Fig. S3C). Nuclear and cell  
347 shrinkage was also observed. Therefore *S. flexneri* infection induced non-apoptotic cell death in  
348 HeLa cells. Since LDH release was observed when HeLa cells were treated with Triton X-100  
349 and not STS, we reasoned that the cell death pathway activated during *Shigella* infection under  
350 the conditions used is most likely necrosis.

351  
352 Next we investigated if components of the programmed necrosis pathway are important during *S.*  
353 *flexneri*-infection. Necrostatin-1 is an allosteric inhibitor of receptor-interacting Ser/Thr kinases  
354 1 (RIP1) (Degterev et al., 2008); necrostatin-7 targets an unknown effector in the programmed  
355 necrosis pathway (Zheng et al., 2008) and necrosulfonamide covalently modifies mixed lineage  
356 kinase domain-like protein (MLKL) to prevent downstream necrosis activation (Sun et al.,  
357 2012). HeLa monolayers infected with *S. flexneri* (moi 1000) were treated with increasing  
358 concentrations of necrostatin-1 or necrostatin-7 or necrosulfonamide or with the DMSO control  
359 alone. No reduction in LDH release was observed (Fig. 2D, 2E and 2F). We also investigated if  
360 *S. flexneri*-induced cell death was a result of oxidative stress. IM-54 inhibits hydrogen peroxide-  
361 induced necrosis (Dodo et al., 2005); and NecroX-2 and NecroX-5 are mitochondria-targeted  
362 ROS and nitrogen oxidative species (NOS) scavengers (Kim et al., 2010). HeLa monolayers  
363 infected with *S. flexneri* (moi 1000) were treated with increasing concentrations of IM-54 or  
364 NecroX-2 or NecroX-5 or with the DMSO control alone. No reduction in LDH release was  
365 observed (Fig. 2G and 2H). Hence *S. flexneri*-induced cell death in HeLa cells is unlikely a  
366 consequent of oxidative stress and is unlikely activated via the RIP1/MLKL programmed  
367 necrosis pathway.

368  
369 ***S. flexneri* infection induces mitochondrial fragmentation**

370 Next we investigated the effects of *S. flexneri* infection on mitochondria of HeLa cells by IF  
371 microscopy. In uninfected and DMSO-treated HeLa cells, the mitochondrial network is long and  
372 tubular (Fig. 3A and 3B). When mitochondrial division is inhibited, tubular mitochondrial  
373 networks becomes interconnected to form net-like structures, or collapse into perinuclear  
374 structures (Smirnova et al., 2001; Smirnova et al., 1998). HeLa cells treated with the Drp1  
375 inhibitor, Mdivi-1, had degenerate perinuclear mitochondrial structures (Fig. 3C). HeLa cells  
376 were either untreated, treated with DMSO or treated with Mdivi-1, and were infected with *S.*

377 *flexneri* (moi 500) for 3.5 hours. Infected HeLa cells treated with Mdivi-1 had significantly  
378 reduced mitochondrial fragmentation ( $17.26 \pm 1.26\%$ ) compared to untreated ( $33.49 \pm 3.40\%$ ) or  
379 DMSO-treated ( $30.88 \pm 1.63\%$ ) HeLa cells (Fig. 3D - 3G). High bacterial loads were also  
380 observed in *Shigella*-infected HeLa cells regardless of treatment (Fig. 3D - 3F).

381  
382 The effect of Drp1 depletion on mitochondrial fragmentation during *S. flexneri* infection was  
383 determined. HeLa cells were mock transfected or transfected with either negative siRNA or Drp1  
384 siRNA, and were infected with *S. flexneri* (moi 500) for 3.5 hours. Drp1-depleted HeLa cells had  
385 significantly reduced mitochondrial fragmentation ( $15.94 \pm 2.55\%$ ) compared with mock-  
386 transfected ( $27.65 \pm 0.38\%$ ) or negative siRNA-treated ( $27.88 \pm 0.10\%$ ) HeLa cells during  
387 *Shigella* infection (Fig. 4A - 4D). No differences in bacterial loads were observed in infected  
388 cells regardless of treatment. Therefore *S. flexneri* infection in HeLa cells increased Drp1  
389 dependent mitochondrial fragmentation.

390  
391 **Drp1 is important for *S. flexneri* cell to cell spreading but not protrusion formation**  
392 Dynasore, an inhibitor of dynamin II and Drp1 GTPase reduced *S. flexneri* cell to cell spreading.  
393 Dynamin II knockdown with siRNA also significantly affected *S. flexneri* infectious foci  
394 formation (Lum et al., 2013). We decided to investigate if Drp1 also played a role during *S.*  
395 *flexneri* cell to cell spreading. The effects of Mdivi-1 and Drp1 siRNA on infectious foci or  
396 plaque formation by *S. flexneri* were determined. Initial experiment showed that Mdivi-1 could  
397 not be used in the plaque assay due to precipitation when dissolved in the agar mixture. HeLa  
398 monolayers infected with *S. flexneri* (moi 0.1) were treated with increasing concentrations of  
399 Mdivi-1 in an infectious focus assay. Treatment with 20  $\mu$ M Mdivi-1 reduced foci counts and  
400 foci area ( $*p < 0.05$ ) (Fig. 5A - 5C). To investigate the effect of Drp1 depletion on *S. flexneri* cell  
401 to cell spreading, HeLa cells were transfected with Drp1 siRNA and plaque assay was carried  
402 out. *S. flexneri* formed plaques on HeLa cells treated with Drp1 siRNA with a reduced plaque  
403 diameter but not plaque counts when compared to HeLa cells treated with the negative control  
404 siRNA ( $*p < 0.05$ ) (Fig. 6A - 6C). Therefore Drp1 inhibition with Mdivi-1 as well as siRNA  
405 knockdown reduced *Shigella* cell to cell spreading.

406

407 Reduced or absence of protrusion formation may account for decreased infectious focus and  
408 plaque formation. The role of Drp1 in *S. flexneri* protrusion formation was investigated. HeLa  
409 monolayers infected with *S. flexneri* were treated with the DMSO control or 50  $\mu$ M Mdivi-1 and  
410 the percentage of infected cells with one or more bacteria protrusions were enumerated by  
411 counting >100 cells in each experiment (Fig. 7A and 7B).  $55.40 \pm 1.48\%$  of infected HeLa cells  
412 had one or more protrusions. Protrusion formation was not affected by the DMSO control ( $55.27$   
413  $\pm 2.89\%$ ) or 50  $\mu$ M Mdivi-1 ( $53.51 \pm 0.06\%$ ). Reduced *S. flexneri* intracellular growth could also  
414 account for the reduction in focus area and plaque size, but no differences in bacterial counts  
415 were observed between DMSO and Mdivi-1-treated HeLa cells (Fig. S4).

416

#### 417 **Drp1 is not localised to the F-actin tails**

418 Host proteins have been shown to associate with *S. flexneri* actin tail (Kadurugamuwa et al.,  
419 1991; Lum et al., 2013; Sansonetti et al., 1994). We investigated Drp1 localisation in *S. flexneri*-  
420 infected HeLa cells by IF microscopy. Drp1 was not localised to the *S. flexneri* actin tail in  
421 untreated, DMSO-treated, Mdivi-1-treated or Drp1 siRNA-treated HeLa cells (Fig. 8A - 8D).

422

#### 423 **Effect of Mdivi-1 on *S. flexneri* infection of mice**

424 We next investigated the possible in vivo relevance of the observed association between Drp1  
425 and *S. flexneri* cytotoxicity as well as cell to cell spreading. A mouse Sereny test we established  
426 previously (Lum et al., 2013) was used to determine whether ocular infection by *S. flexneri* could  
427 be inhibited by the administration of Mdivi-1. Mice in two groups were injected IP with Mdivi-1  
428 (30 mg/kg) or vehicle at  $t = -1, 6, 23$  and 30 h, and infected with  $2.5 \times 10^7$  CFUs *S. flexneri*  
429 2457T in the right eye ( $t = 0$ ). The mice in both groups developed ocular inflammation at a  
430 similar rate and the Sereny scores were similar (Fig. S5A and S5B). Although a slight effect on  
431 weight loss was observed on D1, no differences were observed on D2 and D3 (Fig. S5C).

432

#### 433 **Discussion**

434 *Shigella* infection in epithelial cells is an interplay between maintaining a replicative niche for  
435 *Shigella* and elimination of infected cells to prevent further cell spreading, even though cell  
436 death and the ensuing inflammation are at considerable cost to the host (Ashida et al., 2011).  
437 During *Shigella* infection, apoptotic (Lembo-Fazio et al., 2011) or necrotic cell death



438 (Bergounioux et al., 2012; Carneiro et al., 2009; Kobayashi et al., 2013) occurs depending on the  
439 experimental conditions. In both cases changes to the outer or inner mitochondrial membrane are  
440 critical to allow the respective cell death pathways to proceed. In this study we investigated the  
441 role of Drp1, the mitochondrial fission protein, during *Shigella* infection in HeLa cells. *Shigella*  
442 infection for 4 hours at moi 1000 induces high levels of LDH release. Inhibition of Drp1 with  
443 Mdivi-1 as well as Drp1 depletion with siRNA significantly reduced HeLa cell cytotoxicity.

444  
445 Drp1 is recruited to the mitochondria during apoptosis and programmed necrosis. During  
446 apoptosis, pro-apoptotic Bax localises to the outer membrane (OM) of the mitochondria and  
447 colocalises with Mfn2 and activates Drp1 at fission sites (Wasiak et al., 2007). Following  
448 mitochondrial fragmentation, mitochondrial OM permeabilisation (MOMP) and cristae  
449 reorganisation, cytochrome *c* is released and caspases are subsequently activated (Frank et al.,  
450 2001). Upon programmed necrosis induction by tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ), RIP1 and  
451 RIP3 interacts with MLKL (Wang et al., 2012). The RIP1/RIP3/MLKL complex is translocated  
452 to the mitochondria to engage mitochondrial protein phosphatase long variant (PGAM5L)  
453 initially and subsequently PGAM5S (PGAM short variant) on the mitochondrial membrane.  
454 Drp1 GTPase activity is activated via dephosphorylation at Ser637, likely by both PGAM5L and  
455 PGAM5S in situ on the mitochondrial OM (Wang et al., 2012). It is speculated Drp1 activation  
456 may cause mitochondrial fragmentation resulting in reduced ATP production, ROS generation or  
457 other downstream events (Wang et al., 2012).

458  
459 We next investigated if components of apoptosis or programmed necrosis are activated during  
460 *Shigella* infection. HeLa cells treated with STS to induce apoptosis resulted in caspase-3  
461 activation as expected (Nicolier et al., 2009), but no significant LDH release was detected in the  
462 culture supernatant. Unsurprisingly pan-caspase inhibition with Z-VAD-fmk or its inactive  
463 analogue, Z-FA-fmk did not affect LDH release in *Shigella*-infected HeLa cells. Inhibition of  
464 programmed necrosis components such RIP1 and MLKL did not reduce LDH release during  
465 *Shigella* infection. ROS and NOS inhibitors also had no effect on LDH release. During *Shigella*  
466 infection (moi 500, 3.5 h), mitochondrial fragmentation was observed in ~ 30% of HeLa cells.  
467 Mitochondrial fragmentation in infected HeLa cells was halved when Drp1 was inhibited with  
468 Mdivi-1 or depleted with siRNA. Previously mitochondrial fragmentation was not observed

469 when HeLa cells were infected with *Shigella* for 1 h at moi 50 (Stavru et al., 2011). In that study  
470  $t = 1$  h refers to the 1 h infection time prior to incubation with 80  $\mu\text{g}/\text{mL}$  gentamicin to remove  
471 extracellular bacteria. In our study the equivalent time point is  $t = 0$ . Collectively data from the  
472 previous study and our observations showed during *Shigella* infection, mitochondrial  
473 fragmentation occurs at a later time point and/or at a much higher moi. In spite of the high  
474 bacterial load, HeLa cells remain intact and alive, similar to observations reported earlier (Mantis  
475 et al., 1996).

476

477 Overall our results suggest that at high moi, *Shigella* infection induces non-apoptotic HeLa cell  
478 death which is mediated by Drp1 and accompanied by mitochondrial fragmentation. Furthermore  
479 HeLa cell death induction during *Shigella* infection is also not dependent on the RIP1/MLKL  
480 programmed necrosis pathway. Previously hallmarks of necrosis such as loss of mitochondrial  
481 inner potential, nuclear and plasma membrane swelling were observed at 8 h post infection in  
482 MEFs infected with *Shigella* (strain M90T) at moi 100 (Carneiro et al., 2009). ROS generation  
483 was also observed 10 h post infection (Carneiro et al., 2009). Consistent with previous finding,  
484 ROS scavengers had no effect on LDH release at 4 h post infection in this study. Mitochondrial  
485 swelling was reported in HaCat cells infected with *S. flexneri* strain YSH6000 at moi 25 for 2 h  
486 (Kobayashi et al., 2013). Changes to mitochondrial morphology observed previously might now  
487 be attributed to Drp1-mediated mitochondrial fragmentation.

488

489 Mitochondrial fission during host cell death in other bacterial infections have been reported,  
490 although Drp1 involvement is not essential. The pore-forming vacuolating cytotoxin A (VacA)  
491 toxin of the gastric pathogen, *Helicobacter pylori*, recruits and activates Drp1 resulting in  
492 mitochondrial fission, Bax activation, MOMP and cytochrome *c* release (Jain et al., 2011). Drp1  
493 fission however is not a prerequisite for VacA-mediated MOMP (Jain et al., 2011). Another  
494 pore-forming toxin, listeriolysin O (LLO) from *Listeria monocytogenes*, the causative agent of  
495 food-borne listeriosis, was reported to fragment mitochondrial networks in HeLa cells, followed  
496 by subsequent decrease in the mitochondrial membrane potential and ATP levels (Stavru et al.,  
497 2011). Intriguingly the Drp1 receptor, Mff, is degraded resulting in reduced Drp1 at the  
498 mitochondria following *Listeria* infection or LLO treatment but mitochondrial fission is not  
499 disrupted (Stavru et al., 2013). It appears the endoplasmic reticulum and the actin cytoskeleton

500 facilitates mitochondrial fission independent of Drp1, although the exact mechanism is not  
501 known.

502

503 Earlier we reported dynasore treatment and dynamin II knockdown with siRNA reduced *Shigella*  
504 cell spreading in HeLa cells (Lum et al., 2013). Dynasore is a non-competitive, reversible  
505 inhibitor of dynamin II and Drp1 GTPase activity. We decided to investigate Drp1's role, if any,  
506 in *Shigella* infectious focus and plaque formation. Drp1 inhibition with Mdivi-1 reduced *Shigella*  
507 cell spreading in a dose dependant manner and Drp1 knockdown with siRNA also reduced  
508 *Shigella* plaque size. Previously Drp1 was reported to colocalise with F-actin stress fibers in  
509 Cos-1 cells, an immortalized mammalian fibroblastic cell line (DuBoff et al., 2012). We did not  
510 observe any interactions between Drp1 and either the F-actin cytoskeleton or the *Shigella* F-actin  
511 tail via IF microscopy in this study. High levels of Drp1 were detected by microscopy in Cos-1  
512 cells (DuBoff et al., 2012), however low levels of Drp1 was observed in HeLa cells in our study.  
513 Hence it is possible Drp1 recruitment to HeLa cell F-actin cytoskeleton and/or *Shigella* F-actin  
514 tail may not be evident due to technical limitations.

515

516 A study in *Potoroo tridactylis* kidney epithelial (PtK2) cells showed that *Listeria* cell spreading  
517 in areas with high mitochondrial density (perinuclear region) had increased mean speed and  
518 greater curvature in trajectories compared to areas with low mitochondrial density (cell  
519 periphery) (Lacayo and Theriot, 2004). *Listeria* and *Shigella* both mediate actin based motility  
520 for cell spreading (Gouin et al., 2005). Inhibition of Drp1 forms net-like mitochondrial networks,  
521 which can collapse into perinuclear structures (Smirnova et al., 2001; Smirnova et al., 1998).  
522 Hence Mdivi-1 treatment would alter the intracellular millieu of HeLa cells dramatically, such  
523 that *Shigella* intracellular speed and movement would be adversely affected. In Mdivi-1 treated  
524 cells, F-actin comet tail formation, intracellular bacterial growth and protrusion formation was  
525 not affected. Hence *Shigella* protrusion formation is not likely to be dependent on its intracellular  
526 motility. Lacoya and Theriot (2004) also observed that MitoTracker Red-labeled mitochondria  
527 had loss of fluorescent label post *Listeria* collision, presumably due to loss of mitochondrial  
528 integrity and transmembrane potential. In this study, we also noticed on some occasions that  
529 MitoTracker Red labeling was more intense in uninfected HeLa cells compared to infected cells.

530

531 Since Mdivi-1 was able to reduce *Shigella* cell spreading and HeLa cell cytotoxicity, the drug's  
532 efficacy was tested in vivo in a murine keratoconjunctivitis (Sereny) model we used previously  
533 (Lum et al., 2013). However Mdivi-1 treatment did not ameliorate conjunctivitis, at least under  
534 the dosing protocol used in these studies. Since an  $\Delta icsA$  mutant is not pathogenic in this model  
535 (Lum et al., 2013), this suggest that Mdivi-1 does not significantly impair intercellular spreading  
536 in vivo. It is possible that the dosing regime used here was not sufficient to maintain an effective  
537 concentration of drug in vivo.

538

539 In conclusion, Drp1 and mitochondrial dynamics play important roles in different aspects of  
540 *Shigella* pathogenesis. During *Shigella* infection, mitochondrial fission following cell death  
541 pathway activation is important to eliminate infected cells. Furthermore loss of mitochondrial  
542 networks disrupts *Shigella*'s ability to mediate cell spreading. Loss of mitochondrial structure  
543 may have altered the intracellular movement of *Shigella*. Although *Shigella* protrusion formation  
544 was not affected, the inefficient intracellular movement over an extended period of time in the  
545 duration of both the infectious focus and plaque assay may retard *Shigella*'s movement from one  
546 cell to the next, resulting in reduced infectious focus area and plaque size. Since the conditions  
547 used to study cell death and cell spreading differ necessarily in HeLa cell confluency, moi and  
548 time of infection, it is difficult to speculate if there are any correlations between cell death, cell  
549 spreading and mitochondrial structure. Future work should focus on how Drp1 is recruited and  
550 activated during *Shigella* infection and if disruption of mitochondrial dynamics would also affect  
551 other bacteria which rely on actin based motility for host dissemination.

552

### 553 **Acknowledgements**

554 We are grateful to Dr. Stephen R. Attridge for assistance with the mouse studies. This work is  
555 supported by a Program Grant (565526) from the National Health and Medical Research Council  
556 (NHMRC) of Australia. ML was the recipient of the Australian Postgraduate Award from the  
557 NHMRC.

558

### 559 **References**

560 Ashida, H., Mimuro, H., Ogawa, M., Kobayashi, T., Sanada, T., Kim, M., Sasakawa, C., 2011. Cell death  
561 and infection: a double-edged sword for host and pathogen survival. *J. Cell Biol.* 195, 931-942.

- 562 Bardhan, P., Faruque, A., Naheed, A., Sack, D., 2010. Decrease in Shigellosis-related deaths without  
563 *Shigella* spp.-specific interventions, Asia. *Emerg. Infect. Dis.* 16, 1718-1723.
- 564 Bergounioux, J., Elisee, R., Prunier, A.-L., Donnadiou, F., Sperandio, B., Sansonetti, P., Arbibe, L., 2012.  
565 Calpain Activation by the *Shigella flexneri* Effector VirA Regulates Key Steps in the Formation and Life of  
566 the Bacterium's Epithelial Niche. *Cell Host & Microbe* 11, 240-252.
- 567 Bernardini, M.L., Mounier, J., d'Hauteville, H., Coquis-Rondon, M., Sansonetti, P.J., 1989. Identification of  
568 *icsA*, a plasmid locus of *Shigella flexneri* that governs bacterial intra- and intercellular spread through  
569 interaction with F-actin. *Proc. Natl. Acad. Sci. U. S. A.* 86, 3867-3871.
- 570 Bishai, E.A., Sidhu, G.S., Li, W., Dhillon, J., Bohil, A.B., Cheney, R.E., Hartwig, J.H., Southwick, F.S., 2012.  
571 Myosin-X Facilitates *Shigella*-induced Membrane Protrusions and Cell-to-Cell Spread. *Cell. Microbiol.* 15,  
572 353-367.
- 573 Carneiro, L.A.M., Travassos, L.H., Soares, F., Tattoli, I., Magalhaes, J.G., Bozza, M.T., Plotkowski, M.C.,  
574 Sansonetti, P.J., Molkentin, J.D., Philpott, D.J., Girardin, S.E., 2009. *Shigella* Induces Mitochondrial  
575 Dysfunction and Cell Death in Nonmyeloid Cells. *Cell Host & Microbe* 5, 123-136.
- 576 Cassidy-Stone, A., Chipuk, J.E., Ingeman, E., Song, C., Yoo, C., Kuwana, T., Kurth, M.J., Shaw, J.T.,  
577 Hinshaw, J.E., Green, D.R., Nunnari, J., 2008. Chemical inhibition of the mitochondrial division dynamin  
578 reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. *Dev. Cell* 14,  
579 193-204.
- 580 Cossart, P., Sansonetti, P.J., 2004. Bacterial Invasion: The Paradigms of Enteroinvasive Pathogens.  
581 *Science* 304, 242-248.
- 582 Degterev, A., Hitomi, J., Germscheid, M., Ch'en, I.L., Korkina, O., Teng, X., Abbott, D., Cuny, G.D., Yuan,  
583 C., Wagner, G., Hedrick, S.M., Gerber, S.A., Lugovskoy, A., Yuan, J., 2008. Identification of RIP1 kinase as  
584 a specific cellular target of necrostatins. *Nat. Chem. Biol.* 4, 313-321.
- 585 Dodo, K., Katoh, M., Shimizu, T., Takahashi, M., Sodeoka, M., 2005. Inhibition of hydrogen peroxide-  
586 induced necrotic cell death with 3-amino-2-indolylmaleimide derivatives. *Bioorg. Med. Chem. Lett.* 15,  
587 3114-3118.
- 588 DuBoff, B., Götz, J., Feany, Mel B., 2012. Tau Promotes Neurodegeneration via DRP1 Mislocalization  
589 In Vivo. *Neuron* 75, 618-632.
- 590 Faherty, C.S., Maurelli, A.T., 2009. Spa15 of *Shigella flexneri* Is Secreted through the Type III Secretion  
591 System and Prevents Staurosporine-Induced Apoptosis. *Infect. Immun.* 77, 5281-5290.
- 592 Ferrari, L.F., Chum, A., Bogen, O., Reichling, D.B., Levine, J.D., 2011. Role of Drp1, a key mitochondrial  
593 fission protein, in neuropathic pain. *J. Neurosci.* 31, 11404-11410.
- 594 Frank, S., Gaume, B., Bergmann-Leitner, E.S., Leitner, W.W., Robert, E.G., Catez, F., Smith, C.L., Youle,  
595 R.J., 2001. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. *Dev.*  
596 *Cell* 1, 515-525.
- 597 Friedman, J.R., Lackner, L.L., West, M., DiBenedetto, J.R., Nunnari, J., Voeltz, G.K., 2011. ER Tubules Mark  
598 Sites of Mitochondrial Division. *Science* 334, 358-362.
- 599 Fukumatsu, M., Ogawa, M., Arakawa, S., Suzuki, M., Nakayama, K., Shimizu, S., Kim, M., Mimuro, H.,  
600 Sasakawa, C., 2012. *Shigella* Targets Epithelial Tricellular Junctions and Uses a Noncanonical Clathrin-  
601 Dependent Endocytic Pathway to Spread Between Cells. *Cell Host Microbe* 11, 325-336.
- 602 Golstein, P., Kroemer, G., 2007. Cell death by necrosis: towards a molecular definition. *Trends Biochem.*  
603 *Sci.* 32, 37-43.
- 604 Gouin, E., Welch, M.D., Cossart, P., 2005. Actin-based motility of intracellular pathogens. *Curr. Opin.*  
605 *Microbiol.* 8, 35-45.
- 606 Heindl, J.E., Saran, I., Yi, C.-r., Lesser, C.F., Goldberg, M.B., 2009. Requirement for formin-induced actin  
607 polymerization during spread of *Shigella*. *Infect. Immun.* 78, 193-203.

- 608 Jain, P., Luo, Z.-Q., Blanke, S.R., 2011. *Helicobacter pylori* vacuolating cytotoxin A (VacA) engages the  
609 mitochondrial fission machinery to induce host cell death. Proc. Natl. Acad. Sci. U. S. A. 108, 16032-  
610 16037.
- 611 Kadurugamuwa, J.L., Rohde, M., Wehland, J., Timmis, K.N., 1991. Intercellular spread of *Shigella flexneri*  
612 through a monolayer mediated by membranous protrusions and associated with reorganization of the  
613 cytoskeletal protein vinculin. Infect. Immun. 59, 3463-3471.
- 614 Kim, H.J., Koo, S.Y., Ahn, B.H., Park, O., Park, D.H., Seo, D.O., Won, J.H., Yim, H.J., Kwak, H.S., Park, H.S.,  
615 Chung, C.W., Oh, Y.L., Kim, S.H., 2010. NecroX as a novel class of mitochondrial reactive oxygen species  
616 and ONOO(-) scavenger. Arch. Pharm. Res. 33, 1813-1823.
- 617 Kobayashi, T., Ogawa, M., Sanada, T., Mimuro, H., Kim, M., Ashida, H., Akakura, R., Yoshida, M., Kawalec,  
618 M., Reichhart, J.-M., Mizushima, T., Sasakawa, C., 2013. The *Shigella* OspC3 Effector Inhibits Caspase-4,  
619 Antagonizes Inflammatory Cell Death, and Promotes Epithelial Infection. Cell Host & Microbe 13, 570-  
620 583.
- 621 Korobova, F., Ramabhadran, V., Higgs, H.N., 2013. An Actin-Dependent Step in Mitochondrial Fission  
622 Mediated by the ER-Associated Formin INF2. Science 339, 464-467.
- 623 Lacayo, C.I., Theriot, J.A., 2004. *Listeria monocytogenes* actin-based motility varies depending on  
624 subcellular location: a kinematic probe for cytoarchitecture. Mol. Biol. Cell 15, 2164-2175.
- 625 Lamkanfi, M., Dixit, V.M., 2010. Manipulation of Host Cell Death Pathways during Microbial Infections.  
626 Cell Host & Microbe 8, 44-54.
- 627 Lembo-Fazio, L., Nigro, G., Noel, G., Rossi, G., Chiara, F., Tsilingiri, K., Rescigno, M., Rasola, A., Bernardini,  
628 M.L., 2011. Gadd45[alpha] activity is the principal effector of *Shigella* mitochondria-dependent epithelial  
629 cell death *in vitro* and *ex vivo*. Cell Death & Dis. 2, e122.
- 630 Lett, M.C., Sasakawa, C., Okada, N., Sakai, T., Makino, S., Yamada, M., Komatsu, K., Yoshikawa, M., 1989.  
631 *virG*, a plasmid-coded virulence gene of *Shigella flexneri*: identification of the *virG* protein and  
632 determination of the complete coding sequence. J. Bacteriol. 171, 353-359.
- 633 Lum, M., Attridge, S.R., Morona, R., 2013. Impact of Dynasore an Inhibitor of Dynamin II on *Shigella*  
634 *flexneri* Infection. PLoS One 8, e84975.
- 635 Makino, S., Sasakawa, C., Kamata, K., Kurata, T., Yoshikawa, M., 1986. A genetic determinant required  
636 for continuous reinfection of adjacent cells on large plasmid in *S. flexneri* 2a. Cell 46, 551-555.
- 637 Mantis, N., Prévost, M.C., Sansonetti, P., 1996. Analysis of epithelial cell stress response during infection  
638 by *Shigella flexneri*. Infect. Immun. 64, 2474-2482.
- 639 Morona, R., Daniels, C., Van Den Bosch, L., 2003. Genetic modulation of *Shigella flexneri* 2a  
640 lipopolysaccharide O antigen modal chain length reveals that it has been optimized for virulence.  
641 Microbiol. 149, 925-939.
- 642 Morona, R., Van Den Bosch, L., 2003. Lipopolysaccharide O antigen chains mask IcsA (VirG) in *Shigella*  
643 *flexneri*. FEMS Microbiol. Lett. 221, 173-180.
- 644 Murayama, S.Y., Sakai, T., Makino, S., Kurata, T., Sasakawa, C., Yoshikawa, M., 1986. The use of mice in  
645 the Sereny test as a virulence assay of Shigellae and enteroinvasive *Escherichia coli*. Infect. Immun. 51,  
646 696-698.
- 647 Nicolier, M., Decrion-Barthod, A.-Z., Launay, S., Prétet, J.-L., Mouglin, C., 2009. Spatiotemporal activation  
648 of caspase-dependent and -independent pathways in staurosporine-induced apoptosis of p53wt and  
649 p53mt human cervical carcinoma cells. Biol. Cell. 101, 455-467.
- 650 Oaks, E.V., Wingfield, M.E., Formal, S.B., 1985. Plaque formation by virulent *Shigella flexneri*. Infect.  
651 Immun. 48, 124-129.
- 652 Ong, S.B., Subrayan, S., Lim, S.Y., Yellon, D.M., Davidson, S.M., Hausenloy, D.J., 2010. Inhibiting  
653 mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation 121, 2012-2022.
- 654 Otera, H., Ishihara, N., Mihara, K., 2013. New insights into the function and regulation of mitochondrial  
655 fission. BBA-Mol. Cell. Res. 1833, 1256-1268.

656 Otera, H., Wang, C., Cleland, M.M., Setoguchi, K., Yokota, S., Youle, R.J., Mihara, K., 2010. Mff is an  
657 essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells.  
658 J. Cell Biol. 191, 1141-1158.

659 Reed, J.C., 2000. Mechanisms of apoptosis. Am. J. Pathol. 157, 1415-1430.

660 Sansonetti, P.J., Mounier, J., Prévost, M.C., Mege, R.M., 1994. Cadherin expression is required for the  
661 spread of *Shigella flexneri* between epithelial cells. Cell 76, 829-839.

662 Sansonetti, P.J., Phalipon, A., Arondel, J., Thirumalai, K., Banerjee, S., Akira, S., Takeda, K., Zychlinsky, A.,  
663 2000. Caspase-1 activation of IL-1beta and IL-18 are essential for *Shigella flexneri*-induced inflammation.  
664 Immunity 12, 581-590.

665 Sansonetti, P.J., Ryter, A., Clerc, P., Maurelli, A.T., Mounier, J., 1986. Multiplication of *Shigella flexneri*  
666 within HeLa cells: lysis of the phagocytic vacuole and plasmid-mediated contact hemolysis. Infect.  
667 Immun. 51, 461-469.

668 Schuch, R., Sandlin, R.C., Maurelli, A.T., 1999. A system for identifying post-invasion functions of invasion  
669 genes: requirements for the Mxi-Spa type III secretion pathway of *Shigella flexneri* in intercellular  
670 dissemination. Mol. Microbiol. 34, 675-689.

671 Senerovic, L., Tsunoda, S.P., Goosmann, C., Brinkmann, V., Zychlinsky, A., Meissner, F., Kolbe, M., 2012.  
672 Spontaneous formation of IpaB ion channels in host cell membranes reveals how *Shigella* induces  
673 pyroptosis in macrophages. Cell Death Dis. 3, e384.

674 Smirnova, E., Griparic, L., Shurland, D.-L., van der Bliek, A.M., 2001. Dynamin-related Protein Drp1 Is  
675 Required for Mitochondrial Division in Mammalian Cells. Mol. Biol. Cell 12, 2245-2256.

676 Smirnova, E., Shurland, D.-L., Ryazantsev, S.N., van der Bliek, A.M., 1998. A Human Dynamin-related  
677 Protein Controls the Distribution of Mitochondria. J. Cell Biol. 143, 351-358.

678 Stavru, F., Bouillaud, F., Sartori, A., Ricquier, D., Cossart, P., 2011. *Listeria monocytogenes* transiently  
679 alters mitochondrial dynamics during infection. Proc. Natl. Acad. Sci. U. S. A. 108, 3612-3617.

680 Stavru, F., Palmer, A.E., Wang, C., Youle, R.J., Cossart, P., 2013. Atypical mitochondrial fission upon  
681 bacterial infection. Proc. Natl. Acad. Sci. U. S. A. 110, 16003-16008.

682 Sun, L., Wang, H., Wang, Z., He, S., Chen, S., Liao, D., Wang, L., Yan, J., Liu, W., Lei, X., Wang, X., 2012.  
683 Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell  
684 148, 213-227.

685 Suzuki, T., Franchi, L., Toma, C., Ashida, H., Ogawa, M., Yoshikawa, Y., Mimuro, H., Inohara, N.,  
686 Sasakawa, C., Nunez, G., 2007. Differential regulation of caspase-1 activation, pyroptosis, and autophagy  
687 via IpaB and ASC in *Shigella*-infected macrophages. PLoS Pathog. 3, e111.

688 Tang, W.X., Wu, W.H., Qiu, H.Y., Bo, H., Huang, S.M., 2013. Amelioration of rhabdomyolysis-induced  
689 renal mitochondrial injury and apoptosis through suppression of Drp-1 translocation. J. Nephrol. 26,  
690 1073-1082.

691 Tran Van Nhieu, G., Clair, C., Bruzzone, R., Mesnil, M., Sansonetti, P., Combettes, L., 2003. Connexin-  
692 dependent inter-cellular communication increases invasion and dissemination of *Shigella* in epithelial  
693 cells. Nat. Cell Biol. 5, 720-726.

694 Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., Kroemer, G., 2010. Molecular mechanisms of  
695 necroptosis: an ordered cellular explosion. Nat. Rev. Mol. Cell Biol. 11, 700-714.

696 Wang, Z., Jiang, H., Chen, S., Du, F., Wang, X., 2012. The Mitochondrial Phosphatase PGAM5 Functions at  
697 the Convergence Point of Multiple Necrotic Death Pathways. Cell 148, 228-243.

698 Wasiak, S., Zunino, R., McBride, H.M., 2007. Bax/Bak promote sumoylation of DRP1 and its stable  
699 association with mitochondria during apoptotic cell death. J. Cell Biol. 177, 439-450.

700 Willingham, S.B., Bergstralh, D.T., O'Connor, W., Morrison, A.C., Taxman, D.J., Duncan, J.A., Barnoy, S.,  
701 Venkatesan, M.M., Flavell, R.A., Deshmukh, M., Hoffman, H.M., Ting, J.P., 2007. Microbial pathogen-  
702 induced necrotic cell death mediated by the inflammasome components CIAS1/cryopyrin/NLRP3 and  
703 ASC. Cell Host Microbe 2, 147-159.

704 Zheng, W., Degterev, A., Hsu, E., Yuan, J., Yuan, C., 2008. Structure-activity relationship study of a novel  
705 necroptosis inhibitor, necrostatin-7. *Bioorg. Med. Chem. Lett.* 18, 4932-4935.  
706  
707

Accepted Manuscript



707

708 **Figures**

709 **Figure 1. Drp1 mediates *S. flexneri* 2457T-induced HeLa cell death.** (A) HeLa cells were  
710 infected with *S. flexneri* 2457T (moi 1000) in a 96-well tray for 1 h, followed by incubation with  
711 MEM containing 40 µg/mL of gentamicin to exclude extracellular bacteria for 4 h as described  
712 in the Methods. LDH release was measured in the presence of DMSO or Mdivi-1. Data are  
713 represented as mean ± SEM of independent experiments (n = 3), analysed with one-way  
714 ANOVA ( $p < 0.0001$ ), followed by Tukey's post hoc test ( $*p < 0.05$ ,  $***p < 0.001$ ,  $****p <$   
715  $0.0001$ ). No differences in LDH release were observed in the presence of Mdivi-1 or DMSO in  
716 the absence of bacterial infection (B - C) HeLa cells were either mock transfected or transfected  
717 with control or Drp1 siRNA for 24 h, trypsinised and re-transfected for further 24 h. (B) HeLa  
718 cell extracts were probed with anti-Drp1. GAPDH was used as a loading control. (C) Post  
719 transfection, HeLa cells were infected with *S. flexneri* 2457T in a 96-well tray as described in  
720 (A). Data are represented as mean ± SEM of independent experiments (n = 2), analysed with  
721 one-way ANOVA ( $p = 0.0129$ ), followed by Tukey's post hoc test ( $*p < 0.05$ ).

722

723 **Figure 2. *S. flexneri* 2457T induces non-apoptotic cell death in HeLa cells.** HeLa cells were  
724 infected with *S. flexneri* 2457T (moi 1000) in a 96-well tray for 1 h, followed by incubation with  
725 MEM containing 40 µg/mL of gentamicin to exclude extracellular bacteria for 4 h as described  
726 in the Methods. LDH release was measured in the presence of DMSO or (A) Staurosporine  
727 (STS) or 0.01% Triton X-100, (B) Z-VAD-fmk, (C) Z-FA-fmk, (D) Necrostatin-1, (E)  
728 Necrostatin-7, (F) Necrosulfonamide, (G) IM-54, (H) NecroX-2 or NecroX-5. Data are  
729 represented as mean ± SEM of independent experiments (n = 3). (B) - (H) were analysed with  
730 one-way ANOVA ( $p = 0.0495$  for Z-VAD-fmk,  $p > 0.05$  for Z-FA-fmk,  $p = 0.0073$  for  
731 Necrostatin-1,  $p = 0.0458$  for Necrostatin-7,  $p > 0.05$  for Necrosulfonamide,  $p = 0.0193$  for IM-  
732 54, and  $p > 0.05$  for NecroX-2 and NecroX-5), followed by Tukey's post hoc test. No differences  
733 in LDH release were observed in the presence of the specific chemicals or DMSO in the absence  
734 of bacterial infection.

735

736 **Figure 3. Drp1 inhibition with Mdivi-1 reduces mitochondrial fragmentation in HeLa cells**  
737 **during *S. flexneri* 2457T infection.** HeLa cells were infected with *S. flexneri* 2457T (moi 500)

24

738 for 1 h, followed by incubation with MEM containing 40 µg/mL of gentamicin to exclude  
739 extracellular bacteria for 3.5 h as described in the Methods. Bacteria and HeLa nuclei were  
740 stained with DAPI and mitochondria was stained with MitoTracker® Red CMXRos. Images  
741 were taken at 100× magnification. Scale bar = 10 µm. The last column is 2.5× magnifications of  
742 the respective boxed areas in the MitoTracker® Red CMXRos images. (A) - (F) Uninfected or  
743 2457T-infected HeLa cells were treated with DMSO or Mdivi-1; (A) HeLa; (B) HeLa + DMSO;  
744 (C) HeLa + 50 µM Mdivi-1; (D) 2457T; (E) 2457T + DMSO ; (F) 2457T + 50 µM Mdivi-1. (G)  
745 The percentage of cells with fragmented mitochondria was determined by counting >100 cells in  
746 each experiment. Data are represented as mean ± SEM of independent experiments (n = 2),  
747 analysed with one-way ANOVA ( $p = 0.0289$ ), followed by Tukey's post hoc test ( $*p < 0.05$ ).

748  
749 **Figure 4. Transfection of HeLa cells with Drp1 siRNA reduces mitochondrial**  
750 **fragmentation in HeLa cells during *S. flexneri* 2457T infection.** HeLa cells were either mock  
751 transfected or transfected with control or Drp1 siRNA for 24 h, trypsinised and re-transfected for  
752 further 24 h. HeLa cells were infected with *S. flexneri* 2457T (moi 500) for 1 h, followed by  
753 incubation with MEM containing 40 µg/mL of gentamicin to exclude extracellular bacteria for  
754 3.5 h as described in the Methods. Bacteria and HeLa nuclei were stained with DAPI and  
755 mitochondria was stained with MitoTracker® Red CMXRos. Images were taken at 100×  
756 magnification. Scale bar = 10 µm. The last column is 2.5× magnifications of the respective  
757 boxed areas in the MitoTracker® Red CMXRos images. (A) - (C) Mock, control siRNA and  
758 Drp1 siRNA transfected HeLa cells were infected with 2457T; (A) Mock transfected; (B)  
759 Control siRNA; (C) Drp1 siRNA. (D) The percentage of cells with fragmented mitochondria was  
760 determined by counting >100 cells in each experiment. Data are represented as mean ± SEM of  
761 independent experiments (n = 2), analysed with one-way ANOVA ( $p < 0.0001$ ), followed by  
762 Tukey's post hoc test ( $*p < 0.05$ ).

763  
764 **Figure 5. Drp1 inhibition with Mdivi-1 reduces *S. flexneri* MLRM107 foci counts and foci**  
765 **area.** HeLa cells were infected with *S. flexneri* MLRM107 in an infectious focus assay using a  
766 12-well tray as described in the Methods. Infectious foci were imaged 24 h post gentamicin  
767 treatment. (A) Images shown are overlay of an image taken with phase contrast and TxRed filter  
768 (10× magnification). The area of the infectious focus i.e. area where mCherry was detected, is

769 outlined. Scale bar = 0.1 mm. (B) The total foci counts from one well or (C) mean foci area from  
770 one well were calculated. Data are represented as mean  $\pm$  SEM of independent experiments (n =  
771 3), analysed with one-way ANOVA ( $p = 0.0013$  for foci counts and  $p = 0.0003$  mean foci area),  
772 followed by Tukey's post hoc test ( $*p < 0.05$ ,  $**p < 0.01$ ,  $***p < 0.001$ ).

773

774 **Figure 6. HeLa cells transfected with Drp1 siRNA reduces *S. flexneri* 2457T plaque size.**

775 HeLa cells were either mock transfected or transfected with control or Drp1 siRNA for 24 h,  
776 trypsinised and re-transfected for further 24 h. HeLa cells were infected with *S. flexneri* 2457T in  
777 a plaque assay using a 6-well tray as described in the Methods. (A) Wells were stained with  
778 Neutral Red to makes plaques more visible. Scale bar = 2 mm. (B) The total plaque counts or (C)  
779 mean plaque diameters from each well infected with *Shigella* were calculated. Data are  
780 represented as mean  $\pm$  SEM of independent experiments (n = 2), analysed with one-way  
781 ANOVA ( $p > 0.05$  for plaque counts and  $p = 0.0239$  mean plaque diameters), followed by  
782 Tukey's post hoc test ( $*p < 0.05$ ).

783

784 **Figure 7. *S. flexneri* 2457T protrusion is not affected in the presence of Mdivi-1.** HeLa cells

785 were infected with *S. flexneri* 2457T for 1 h in a 24-well tray. HeLa cells were washed thrice  
786 with D-PBS and incubated with MEM containing 40  $\mu\text{g}/\text{mL}$  of gentamicin (t=0) to exclude  
787 extracellular bacteria. Concurrently HeLa cells were treated with 50  $\mu\text{M}$  Mdivi-1 or DMSO for  
788 1.5 h. At t = 1.5, HeLa cells were fixed to observe bacteria protrusions. (A) Infected HeLa cells  
789 were imaged at 40 $\times$  magnification. Scale bar = 10  $\mu\text{m}$ . The arrows indicate protrusion formation.  
790 Insert shows 2 $\times$  enlargement of the indicated region. (B) The percentage of infected cells with  
791 bacteria protrusion(s) were enumerated by counting >100 cells in each independent experiment.  
792 Data are represented as mean  $\pm$  SEM of independent experiments (n = 2), analysed with one-way  
793 ANOVA ( $p > 0.05$ ).

794

795 **Figure 8. Drp1 is not localised to the *S. flexneri* 2457T F-actin tails.** HeLa cells were infected

796 with *S. flexneri* 2457T in an invasion assay as described in the Methods. Bacteria and HeLa  
797 nuclei were stained with DAPI (blue), F-actin was stained with FITC-phalloidin (green) and  
798 Drp1 was stained with anti-Drp1 and Alexa Fluor 594-conjugated secondary antibody (red).  
799 Images were taken at 100 $\times$  magnification. Scale bar = 10  $\mu\text{m}$ . (A) - (D) HeLa cells were treated


800 with DMSO, Mdivi-1 or were transfected with Drp1 siRNA and were infected with *S. flexneri*  
801 2457T; (A) Untreated; (B) 1% DMSO; (C) 50  $\mu$ M Mdivi-1; (D) Drp1 siRNA transfected HeLa  
802 cells. Arrows indicate F-actin comet tails. The experiment was repeated twice and representative  
803 images are shown.


804


828

829


Accepted Manuscript













uscrip














1 **Table 1.** Bacterial strains

Strain	Relevant characteristics <sup>#</sup>	Reference or source
<i>S. flexneri</i>		
2457T	<i>S. flexneri</i> 2a wild type	Laboratory collection
MLRM107	2457T [pMP7604; Tc <sup>R</sup> ]	(Lum et al., 2013)
RMA2159	Virulence plasmid-cured 2457T	Laboratory collection

2 # Tet<sup>R</sup>, Tetracycline resistant

3

4 Lum, M., Attridge, S.R., Morona, R., 2013. Impact of Dynasore an Inhibitor of Dynamin II on *Shigella*  
5 *flexneri* Infection. PLoS One 8, e84975.

6

7